Furthermore, Gel-BLyS was shown to lead to downregulation of interleukin-6 receptor, a protein that is highly expressed in diffuse large B cell lymphoma (DLBCL) and impacts the STAT3 targets c-Myc, p21, Mcl-1, and Bcl-xL [69]. The gene discussed is BCL2L1; the disease is diffuse large B-cell lymphoma.